A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab in Frequent Episodic Migraine Prevention: Primary Results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Effi-MedSci.cn

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab in Frequent Episodic Migraine Prevention: Primary Results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Effi

Saper, J; Lipton, R; Kudrow, D; Hirman, J; Dodick, D; Silberstein, S; Chakhava, G; Smith, J; Biondi, D

CEPHALALGIA, 2017; 37 ( ): 337

科室
- - 订阅+
  - 更多科室
工具
服务